Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Lipidomics unveils lipid dyshomeostasis and low circulating plasmalogens as biomarkers in a monogenic mitochondrial disorder
Matthieu Ruiz, Alexanne Cuillerier, Caroline Daneault, Sonia Deschênes, Isabelle Robillard Frayne, Bertrand Bouchard, Anik Forest, Julie Thompson Legault, The LSFC Consortium, Frederic M. Vaz, John D. Rioux, Yan Burelle, Christine Des Rosiers
Matthieu Ruiz, Alexanne Cuillerier, Caroline Daneault, Sonia Deschênes, Isabelle Robillard Frayne, Bertrand Bouchard, Anik Forest, Julie Thompson Legault, The LSFC Consortium, Frederic M. Vaz, John D. Rioux, Yan Burelle, Christine Des Rosiers
View: Text | PDF
Research Article Cell biology Metabolism

Lipidomics unveils lipid dyshomeostasis and low circulating plasmalogens as biomarkers in a monogenic mitochondrial disorder

  • Text
  • PDF
Abstract

Mitochondrial dysfunction characterizes many rare and common age-associated diseases. The biochemical consequences, underlying clinical manifestations, and potential therapeutic targets, remain to be better understood. We tested the hypothesis that lipid dyshomeostasis in mitochondrial disorders goes beyond mitochondrial fatty acid β-oxidation, particularly in liver. This was achieved using comprehensive untargeted and targeted lipidomics in a case-control cohort of patients with Leigh syndrome French-Canadian variant (LSFC), a mitochondrial disease caused by mutations in LRPPRC, and in mice harboring liver-specific inactivation of Lrpprc (H-Lrpprc–/–). We discovered a plasma lipid signature discriminating LSFC patients from controls encompassing lower levels of plasmalogens and conjugated bile acids, which suggest perturbations in peroxisomal lipid metabolism. This premise was reinforced in H-Lrpprc–/– mice, which compared with littermates recapitulated a similar, albeit stronger peroxisomal metabolic signature in plasma and liver including elevated levels of very-long-chain acylcarnitines. These mice also presented higher transcript levels for hepatic markers of peroxisome proliferation in addition to lipid remodeling reminiscent of nonalcoholic fatty liver diseases. Our study underscores the value of lipidomics to unveil unexpected mechanisms underlying lipid dyshomeostasis ensuing from mitochondrial dysfunction herein implying peroxisomes and liver, which likely contribute to the pathophysiology of LSFC, but also other rare and common mitochondrial diseases.

Authors

Matthieu Ruiz, Alexanne Cuillerier, Caroline Daneault, Sonia Deschênes, Isabelle Robillard Frayne, Bertrand Bouchard, Anik Forest, Julie Thompson Legault, The LSFC Consortium, Frederic M. Vaz, John D. Rioux, Yan Burelle, Christine Des Rosiers

×

Figure 2

Targeted profiling of acylcarnitines (ACs) and lysophosphatidylcholine (LPC) 26:0 and unconjugated/conjugated bile acids (BAs) reveals additional lipid perturbations in plasma from LSFC patients.

Options: View larger image (or click on image) Download as PowerPoint
Targeted profiling of acylcarnitines (ACs) and lysophosphatidylcholine (...
(A and B) LC-QQQ–based profiling of 91 ACs in plasma from LSFC patients (gray; n = 9) and controls (white; n = 9) after a nutrient-uptake challenge. (A) Dot plot of P values obtained using paired Student’s t test analysis for the various AC species: short-chain (SCAC, black), medium-chain (MCAC, red), long-chain (LCAC, orange), hydroxylated short/medium–chain (S/MCAC-OH, green), hydroxylated long-chain (LCAC-OH, pink), odd-numbered carbon chain (dark blue), dicarboxylic (DCAC, light blue), and very-long-chain (VLCAC, purple). Significantly elevated ACs are above the dotted line (black P < 0.05, red P-corr < 0.05). (B) Box plots of selected significantly (according to P-corr) elevated AC species in LSFC patients (gray) and controls (white). Cx refers to the number of carbons in the acyl chain of AC species and the symbol # to isomers of AC species, of which the structure remains to be ascertained (e.g., AC#1, AC#2, etc.). (C) Box plots of quantitative values for VLCAC (AC26:0) and LPC 26:0. (D and E) Box plots from LC-QQQ–based profiling of plasma from fasted LSFC patients (gray; n = 4–9) and controls (white; n = 6–9) for (D) unconjugated BA, (E) glyco- and tauro-conjugated BAs. Unequal distribution is ascribed to values below the limit of detection. Statistics using 2-tailed unpaired Student’s t test: *P < 0.05, **P < 0.01, ***P < 0.001 before and $P < 0.05, $$P < 0.01, $$$P < 0.001 after Benjamini-Hochberg correction. CA, cholic acid; CDCA, chenodeoxycholic acid; DCA, deoxycholic acid; GCA, glycocholic acid; GDCA, glycodeoxycholic acid; GCDCA, glycochenodeoxycholic acid; TCA, taurocholic acid; TDCA, taurodeoxycholic acid; TCDCA, taurochenodeoxycholic acid. See also Supplemental Figure 2, A–C, for corresponding plots of results obtained for the fasting and Supplemental Figure 2, D–F, for nutrient-uptake challenge condition.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts